Last reviewed · How we verify
Vitamin C and E
Vitamins C and E act as antioxidants to reduce oxidative stress and cellular damage.
Vitamins C and E act as antioxidants to reduce oxidative stress and cellular damage. Used for Prevention of preeclampsia and related complications in pregnant women, Reduction of adverse pregnancy outcomes in high-risk pregnancies.
At a glance
| Generic name | Vitamin C and E |
|---|---|
| Sponsor | NICHD Global Network for Women's and Children's Health |
| Drug class | Antioxidant vitamin combination |
| Modality | Small molecule |
| Therapeutic area | Obstetrics/Maternal-Fetal Medicine |
| Phase | FDA-approved |
Mechanism of action
Vitamin C (ascorbic acid) and Vitamin E (tocopherol) are fat- and water-soluble antioxidants that neutralize free radicals and reactive oxygen species, protecting cells from oxidative damage. This combination is used to reduce complications in pregnancy and improve maternal and fetal outcomes by mitigating oxidative stress-related pathology.
Approved indications
- Prevention of preeclampsia and related complications in pregnant women
- Reduction of adverse pregnancy outcomes in high-risk pregnancies
Common side effects
- Gastrointestinal upset
- Nausea
- Headache
Key clinical trials
- Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women (PHASE1)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1 (NA)
- Structured Review: To Optimise Management and Prevent Harm in COPD (NA)
- A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (NA)
- A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D) (NA)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin C and E CI brief — competitive landscape report
- Vitamin C and E updates RSS · CI watch RSS
- NICHD Global Network for Women's and Children's Health portfolio CI